Abstract
In recent years, numerous investigations focused on the pleiotropic actions of vitamin D have been carried out. These actions include the participation of this molecule in neurophysiological and neuropathological processes. As a consequence, abundant scientific literature on the role of this vitamin in neurodegenerative entities has emerged, even concerning clinical studies. To identify the level of scientific evidence concerning the relation between vitamin D and neurodegenerative diseases, from a quantitative and qualitative perspective. To describe, by means of a bibliometric analysis, the scientific production and its evolution through time in quantitative terms, regarding the implications of vitamin D in neurodegeneration. To analyse and present the degree of evidence in the aforementioned field of study, a systematic review of the literature focused on the most prevalent neurodegenerative diseases was carried out. We retrieved 848 articles in the bibliometric analysis, the majority of which were dated between the years 2010-2017. The most studied metabolite was the 25(OH)D3 and the most cited disease was multiple sclerosis. In the systematic review, we found studies about Alzheimer’s and Parkinson’s diseases and again, about multiple sclerosis prominently (in number and quality), with 12 randomised double-blind clinical trials. The research about vitamin D and its relations with neurodegenerative diseases shows a growing evolution over the last decade. More studies are needed to find correlations between the clinical severity of these diseases and the specific status of vitamin D and the genotypes related with them, which seems to be a future trend.
Keywords: Vitamin D, VDR gene, neurodegeneration, brain aging, multiple sclerosis, bibliometric analysis, systematic review.
Graphical Abstract
[1]
Pizza V, Agresta A, D’Acunto CW, Festa M, Capasso A. Neuroinflamm-aging and neurodegenerative diseases: An overview. CNS Neurol Disord Drug Targets 2011; 10(5): 621-34.
[2]
Duncan GW. The aging brain and neurodegenerative diseases. Clin Geriatr Med 2011; 27(4): 629-44.
[3]
Morris JC. Neurodegenerative disorders of aging: The down side of rising longevity. Mo Med 2013; 110(5): 393-4.
[4]
Wolfson C, Fereshtehnejad SM, Pasquet R, Postuma R, Keezer MR. High burden of neurological disease in the older general population: Results from the Canadian longitudinal study on aging. Eur J Neurol 2019; 26(2): 356-62.
[5]
Veldurthy V, Wei R, Oz L, Dhawan P, Jeon YH, Christakos S. Vitamin D, calcium homeostasis and aging. Bone Res 2016; 4: 16041.
[6]
de Jongh RT, van Schoor NM, Lips P. Changes in vitamin D endocrinology during aging in adults. Mol Cell Endocrinol 2017; 453: 144-50.
[7]
Bivona G, Agnello L, Ciaccio M. Vitamin D and immunomodulation: Is it time to change the reference values? Ann Clin Lab Sci 2017; 47(4): 508-10.
[8]
Gonçalves de Carvalho CM, Ribeiro SM. Aging, low-grade systemic inflammation and vitamin D: A mini-review. Eur J Clin Nutr 2017; 71(4): 434-40.
[9]
Christakos S, Dhawan P, Verstuyf A. Verlinden L, Carmeliet G,. Vitamin D. Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016; 96(1): 365-408.
[11]
Kalueff AV, Minasyan A, Keisala T, Kuuslahti M, Miettinen S, Tuohimaa P. The vitamin D neuroendocrine system as a target for novel neurotropic drugs. CNS Neurol Disord Drug Targets 2006; 5(3): 363-71.
[12]
Sakuma M, Kitamura K, Endo N, et al. Low serum 25-hydroxyvitamin D increases cognitive impairment in elderly people. J Bone Miner Metab 2019; 37(2): 368-75.
[13]
Gmiąt A, Jaworska J, Micielska K, et al. Improvement of cognitive functions in response to a regular Nordic walking training in elderly women - A change dependent on the training experience. Exp Gerontol 2018; 104: 105-12.
[14]
Kubis AM, Piwowar A. The new insight on the regulatory role of the vitamin D3 in metabolic pathways characteristic for cancerogenesis and neurodegenerative diseases. Ageing Res Rev 2015; 24(Pt B): 126--37.
[16]
Ryan JW, Anderson PH, Morris HA. Pleiotropic activities of vitamin D receptors - adequate activation for multiple health outcomes. Clin Biochem Rev 2015; 36(2): 53-61.
[18]
Eyles DW, Feron F, Cui X, et al. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology 2009; 34(Suppl. 1): S247-57.
[19]
Caprio M, Infante M, Calanchini M, Mammi C, Fabbri A, Vitamin D. Not just the bone. Evidence for beneficial pleiotropic extraskeletal effects. Eat Weight Disord 2017; 22(1): 27-41.
[20]
Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis: An update. Mult Scler Relat Disord 2017; 14: 35-45.
[21]
Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: A comprehensive review. Neurol Ther 2018; 7(1): 59-85.
[22]
Breuer J, Loser K, Mykicki N, Wiendl H, Schwab N. Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D? J Neuroimmunol 2019; 329: 1-8.
[23]
Lazic SE. Statistical evaluation of methods for quantifying gene expression by autoradiography in histological sections. BMC Neurosci 2009; 10: 5.
[24]
Stumpf WE. Whole-body and microscopic autoradiography to determine tissue distribution of biopharmaceuticals -- target discoveries with receptor micro-autoradiography engendered new concepts and therapies for vitamin D. Adv Drug Deliv Rev 2013; 65(8): 1086-97.
[25]
Kalueff AV, Minasyan A, Keisala T, Kuuslahti M, Miettinen S, Tuohimaa P. The vitamin D neuroendocrine system as a target for novel neurotropic drugs. CNS Neurol Disord Drug Targets 2006; 5(3): 363-71.
[26]
Cui X, Gooch H, Petty A, McGrath JJ, Eyles D. Vitamin D and the brain: Genomic and non-genomic actions. Mol Cell Endocrinol 2017; 453: 131-43.
[27]
Landel V, Stephan D, Cui X, Eyles D, Feron F. Differential expression of vitamin D-associated enzymes and receptors in brain cell subtypes. J Steroid Biochem Mol Biol 2018; 177: 129-34.
[28]
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005; 29(1): 21-30.
[29]
Eyles DW, Liu PY, Josh P, Cui X. Intracellular distribution of the vitamin D receptor in the brain: Comparison with classic target tissues and redistribution with development. Neuroscience 2014; 268: 1-9.
[30]
Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology 2014; 83(10): 920-8.
[31]
McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 2008; 22(4): 982-1001.
[32]
Lawrence DW, Sharma B. A review of the neuroprotective role of vitamin D in traumatic brain injury with implications for supplementation post-concussion. Brain Inj 2016; 30(8): 960-8.
[33]
Santos CM. New agents promote neuroprotection in Parkinson’s disease models. CNS Neurol Disord Drug Targets 2012; 11(4): 410-8.
[34]
Orme RP, Middleditch C, Waite L, Fricker RA. The role of vitamin D3 in the development and neuroprotection of midbrain dopamine neurons. Vitam Horm 2016; 100: 273-97.
[35]
Nameni G, Hajiluian G, Shahabi P, et al. The impact of vitamin D supplementation on neurodegeneration, TNF-α concentration in hypothalamus, and CSF-to-plasma ratio of insulin in high-fat-diet-induced obese rats. J Mol Neurosci 2017; 61(2): 247-55.
[36]
Mpandzou G, Aït Ben Haddou E, Regragui W, Benomar A, Yahyaoui M. Vitamin D deficiency and its role in neurological conditions: A review. Rev Neurol (Paris) 2016; 172(2): 109-22.
[37]
Lima LAR, Lopes MJP, Costa RO, et al. Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats. J Neuroinflammation 2018; 15(1): 249.
[38]
Langer-Gould A, Lucas RM, Xiang AH, et al. Vitamin D-binding protein polymorphisms, 25-hydroxyvitamin D, sunshine and multiple sclerosis. Nutrients 2018; 10(2): 84.
[42]
Zhu D, Liu GY, Lv Z, Wen SR, Bi S, Wang WZ. Inverse associations of outdoor activity and vitamin D intake with the risk of Parkinson’s disease. J Zhejiang Univ Sci B 2014; 15(10): 923-7.
[43]
Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr 2013; 97(5): 1004-13.
[44]
Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007; 68(12): 911-5.
[45]
Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 66(1): 64-8.
[46]
van den Bos F, Speelman AD, van Nimwegen M, et al. Bone mineral density and vitamin D status in Parkinson’s disease patients. J Neurol 2013; 260(3): 754-60.
[47]
Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 2011; 68(3): 314-9.
[48]
Abe S, Ezaki O, Suzuki M. Medium-chain triglycerides in combination with leucine and vitamin D benefit cognition in frail elderly adults: A randomized controlled trial. J Nutr Sci Vitaminol (Tokyo) 2017; 63(2): 133-40.
[49]
Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition, and dementia: A systematic review and meta-analysis. Neurology 2012; 79(13): 1397-405.
[50]
Stein MS, Scherer SC, Ladd KS, Harrison LC. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer’s disease. J Alzheimers Dis 2011; 26(3): 477-84.
[51]
O’Connell K, Sulaimani J, Basdeo SA, et al. Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial. Mult Scler J Exp Transl Clin 2017; 3(3)2055217317727296
[52]
Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M. High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. Neurol Res 2016; 38(10): 888-92.
[53]
Røsjø E, Lossius A, Abdelmagid N, et al. Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. Mult Scler 2017; 23(3): 395-402.
[54]
Sotirchos ES, Bhargava P, Eckstein C, et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology 2016; 86(4): 382-90.
[55]
Fitzgerald KC, Munger KL, Köchert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol 2015; 72(12): 1458-65.
[56]
Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M. Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation 2015; 22(6): 400-4.
[57]
Toghianifar N, Ashtari F, Zarkesh-Esfahani SH, Mansourian M. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. J Neuroimmunol 2015; 285: 125-8.
[58]
Achiron A, Givon U, Magalashvili D, et al. Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Mult Scler 2015; 21(6): 767-75.
[59]
Golan D, Halhal B, Glass-Marmor L, et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: A randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol 2013; 13: 60.
[60]
Golan D, Staun-Ram E, Glass-Marmor L, et al. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun 2013; 32: 180-5.
[61]
Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 2013; 40(3): 147-53.
[62]
Derakhshandi H, Etemadifar M, Feizi A, et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: A double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg 2013; 113(3): 257-63.
[63]
James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of vitamin D-related interventions on multiple sclerosis relapses: A meta-analysis. Mult Scler 2013; 19(12): 1571-9.
[64]
Røsjø E, Steffensen LH, Jørgensen L, et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. J Neurol 2015; 262(12): 2713-21.
[65]
Rolf L, Muris AH, Mathias A, et al. Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Mult Scler 2018; 24(10): 1280-7.
[66]
Holmøy T, Lindstrøm JC, Eriksen EF, Steffensen LH, Kampman MT. High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurol 2017; 17(1): 67.
[67]
Hart PH, Lucas RM, Booth DR, et al. Narrowband UVB phototherapy for clinically isolated syndrome: A trial to deliver the benefits of vitamin D and other UVB-induced molecules. Front Immunol 2017; 8: 3.
[68]
Hempel S, Graham GD, Fu N, et al. A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis. Mult Scler 2017; 23(4): 513-24.
[69]
Muris AH, Smolders J, Rolf L, Thewissen M, Hupperts R, Damoiseaux J. Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study. J Neuroimmunol 2016; 300: 47-56.
[70]
Salari M, Janghorbani M, Etemadifar M, Dehghani A, Razmjoo H, Naderian G. Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: Preliminary findings of a randomized, placebo-controlled trial. J Res Med Sci 2015; 20(4): 372-8.
[71]
Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: Preliminary findings of a randomized-controlled trial. Iran J Neurol 2015; 14(2): 67-73.
[72]
Shirvani-Farsani Z, Behmanesh M, Mohammadi SM, Naser Moghadasi A. Vitamin D levels in multiple sclerosis patients: Association with TGF-β2, TGF-βRI, and TGF-βRII expression. Life Sci 2015; 134: 63-7.
[73]
Åivo J, Hänninen A, Ilonen J, Soilu-Hänninen M. Vitamin D3 administration to MS patients leads to increased serum levels of Latency Activated Peptide (LAP) of TGF-beta. J Neuroimmunol 2015; 280: 12-5.
[74]
Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71(3): 306-14.
[75]
Najafipoor A, Roghanian R, Zarkesh-Esfahani SH, Bouzari M, Etemadifar M. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients. Cell Immunol 2015; 294(1): 9-12.
[76]
Bhargava P, Fitzgerald KC, Calabresi PA, Mowry EM. Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. JCI Insight 2017; 2(19): 95302.
[77]
Muris AH, Smolders J, Rolf L, et al. Vitamin D status does not affect disability progression of patients with multiple sclerosis over three-year follow-up. PLoS One 2016; 11(6)e0156122
[78]
Wergeland S, Myhr KM, Løken-Amsrud KI, et al. Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. Eur J Neurol 2016; 23(6): 1064-70.
[79]
Mowry EM, Pelletier D, Gao Z, Howell MD, Zamvil SS, Waubant E. Vitamin D in clinically isolated syndrome: Evidence for possible neuroprotection. Eur J Neurol 2016; 23(2): 327-32.
[80]
Narooie-Nejad M, Moossavi M, Torkamanzehi A, Moghtaderi A. Positive association of vitamin D receptor gene variations with multiple sclerosis in South East Iranian population. BioMed Res Int 2015; 2015427519
[81]
Kubicka K, Pierzchała K. Concentration of 25(OH)D3 and calcium and phosphorus metabolism in patients suffering from relapsing-remitting multiple sclerosis. A pilot study. Neurol Neurochir Pol 2013; 47(2): 126-30.
[82]
Brum DG, Comini-Frota ER, Vasconcelos CC, Dias-Tosta E. Supplementation and therapeutic use of vitamin D in patients with multiple sclerosis: Consensus of the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology. Arq Neuropsiquiatr 2014; 72(2): 152-6.
[83]
O’Connell K, Kelly S, Kinsella K, et al. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: Study protocol for an exploratory randomized double- blind placebo-controlled trial. Trials 2013; 14: 272.
[84]
Bhargava P, Cassard S, Steele SU, et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 2014; 39(2): 288-93.
[85]
Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13(7): 700-22.
[86]
Capriotti T, Noel J, Brissenden S. Multiple sclerosis: An update for home healthcare clinicians. Home Health Now 2018; 36(3): 169-80.
Related Journals
Current Drug Safety
Current Neuropharmacology
Current Pharmaceutical Design
Current Neurovascular Research
Current Pharmaceutical Analysis
Central Nervous System Agents in Medicinal Chemistry
Current Vascular Pharmacology
Current Alzheimer Research
Current Molecular Pharmacology
Current Aging Science
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Frontiers in Clinical Drug Research-Dementia
Article Metrics
59
3
2
1